Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Oct 23  •  12:16PM ET
80.29
Dollar change
+1.00
Percentage change
1.26
%
IndexRUT P/E- EPS (ttm)-3.85 Insider Own41.96% Shs Outstand6.13M Perf Week-2.75%
Market Cap578.44M Forward P/E- EPS next Y-3.32 Insider Trans-16.39% Shs Float4.18M Perf Month9.93%
Enterprise Value525.30M PEG- EPS next Q-0.39 Inst Own43.68% Short Float3.54% Perf Quarter78.54%
Income-17.31M P/S- EPS this Y62.67% Inst Trans5.28% Short Ratio2.75 Perf Half Y80.14%
Sales0.00M P/B9.42 EPS next Y-116.35% ROA-56.71% Short Interest0.15M Perf YTD264.95%
Book/sh8.52 P/C10.86 EPS next 5Y16.55% ROE-59.38% 52W High105.00 -23.53% Perf Year1429.33%
Cash/sh7.39 P/FCF- EPS past 3/5Y-4.06% -15.56% ROIC-33.11% 52W Low4.50 1684.22% Perf 3Y727.73%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility9.51% 10.23% Perf 5Y227.05%
Dividend TTM- EV/Sales- EPS Y/Y TTM-66.95% Oper. Margin- ATR (14)7.80 Perf 10Y-
Dividend Ex-Date- Quick Ratio33.94 Sales Y/Y TTM- Profit Margin- RSI (14)51.16 Recom1.08
Dividend Gr. 3/5Y- - Current Ratio33.94 EPS Q/Q28.41% SMA20-9.06% Beta1.38 Target Price108.82
Payout- Debt/Eq0.00 Sales Q/Q- SMA5027.92% Rel Volume1.43 Prev Close79.29
Employees16 LT Debt/Eq0.00 EarningsAug 12 BMO SMA20083.79% Avg Volume53.68K Price80.29
IPODec 19, 2019 Option/ShortNo / Yes EPS/Sales Surpr.23.63% - Trades Volume34,922 Change1.26%
Date Action Analyst Rating Change Price Target Change
Oct-13-25Initiated Barclays Overweight $125
Sep-09-25Initiated BTIG Research Buy $87
Sep-03-25Initiated Raymond James Strong Buy $80
Sep-03-25Initiated Oppenheimer Outperform $77
Aug-26-25Resumed H.C. Wainwright Buy $70
Jul-07-25Initiated Cantor Fitzgerald Overweight $74
Jun-23-25Initiated Chardan Capital Markets Buy $60
Mar-19-25Resumed Piper Sandler Overweight $76
Jan-10-25Initiated Piper Sandler Overweight $72
Oct-11-24Initiated Rodman & Renshaw Buy $50
Oct-21-25 09:55AM
Oct-16-25 04:33PM
Oct-15-25 08:00AM
Sep-23-25 11:08PM
11:07PM
09:40AM Loading…
09:40AM
Sep-15-25 01:15PM
Sep-14-25 08:00AM
Sep-03-25 08:00AM
Aug-12-25 08:00AM
Jun-26-25 03:24PM
Jun-11-25 09:55AM
07:00AM
Jun-06-25 09:40AM
Jun-03-25 07:00AM
08:00AM Loading…
May-13-25 08:00AM
May-07-25 02:30AM
Apr-30-25 05:37AM
Apr-29-25 08:00AM
Mar-31-25 08:00AM
Mar-21-25 08:50AM
Feb-03-25 07:22PM
Jan-23-25 01:10PM
07:06AM
Dec-31-24 02:36AM
Dec-20-24 09:00AM
Dec-05-24 04:21PM
Dec-03-24 08:00AM
Nov-08-24 08:00AM
Oct-30-24 01:42PM
09:15PM Loading…
Oct-28-24 09:15PM
04:00PM
Oct-25-24 07:31AM
Oct-24-24 07:00AM
Oct-22-24 08:00AM
Oct-16-24 08:28AM
Oct-15-24 08:00AM
Oct-08-24 08:30AM
Oct-07-24 08:00AM
Sep-12-24 08:00AM
Sep-04-24 08:00AM
Aug-27-24 04:05PM
Aug-21-24 08:00AM
Aug-14-24 08:00AM
Aug-12-24 12:24PM
Aug-09-24 02:53PM
08:00AM
08:00AM
Jul-09-24 07:00AM
Jun-25-24 08:00AM
Jun-11-24 07:30AM
Jun-10-24 08:00AM
Jun-05-24 06:15AM
May-24-24 08:00AM
May-17-24 09:55AM
May-09-24 01:55PM
07:00AM
Apr-18-24 08:00AM
Apr-16-24 08:00AM
Apr-10-24 08:00AM
Apr-04-24 09:55AM
Apr-03-24 12:00PM
Mar-28-24 11:53AM
07:00AM
Mar-05-24 07:00AM
Feb-27-24 07:00AM
Feb-23-24 11:55AM
Feb-22-24 07:00AM
Feb-20-24 08:00AM
Nov-09-23 08:37AM
07:00AM
Nov-01-23 07:00AM
Oct-10-23 07:00AM
Sep-05-23 07:00AM
Aug-10-23 07:00AM
Aug-08-23 07:00AM
Jul-11-23 07:00AM
Jun-21-23 07:00AM
Jun-14-23 07:00AM
Jun-01-23 07:00AM
May-29-23 09:55AM
May-11-23 07:00AM
Apr-19-23 09:55AM
Mar-28-23 01:40PM
07:00AM
Mar-27-23 05:00PM
Mar-23-23 07:00AM
Mar-07-23 07:00AM
Feb-27-23 07:00AM
Feb-14-23 12:46PM
07:00AM
Feb-05-23 08:38AM
Jan-26-23 07:00AM
Jan-18-23 07:00AM
Dec-12-22 07:00AM
Nov-18-22 01:10PM
09:55AM
Nov-16-22 10:09AM
07:00AM
Nov-10-22 08:00AM
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tactic Pharma LLC10% OwnerSep 24 '25Sale63.61550,22934,999,957272,026Sep 26 03:53 PM
Tsuchimoto Kim RDirectorJul 14 '25Sale40.008,904356,17111,486Jul 16 09:06 PM
STARR CHRISTOPHER MDirectorJul 14 '25Sale40.0016,800672,0205,173Jul 16 09:03 PM
Robinson ChandlerChief Executive OfficerJul 14 '25Sale40.0016,800672,02073,472Jul 16 09:02 PM
STARR CHRISTOPHER MDirectorJul 14 '25Proposed Sale40.0016,800672,000Jul 14 12:29 PM
Tsuchimoto Kim RDirectorJul 14 '25Proposed Sale40.008,904356,160Jul 14 12:26 PM
Robinson ChandlerOfficerJul 14 '25Proposed Sale40.0016,800672,000Jul 14 12:21 PM
Tactic Pharma LLC10% OwnerApr 02 '25Sale35.0033,3341,166,690822,255Apr 04 07:27 PM
Tactic Pharma LLC10% OwnerApr 02 '25Proposed Sale35.0033,3341,166,806Apr 02 11:45 AM
Radhakrishnan KarthikChief Financial OfficerOct 28 '24Buy16.251,55025,1881,550Oct 30 04:17 PM